Dry Powder Inhaler Market is set to experience a significant growth of 4.6% CAGR from 2021 to 2031
According to Future Market Insights, the global market for dry powder inhaler is slated to exhibit a CAGR of nearly 4.6% during the forecast period (2021-2031), in terms of volume.
Over 4000,000 Mn units of dry powder inhaler are pegged to be sold across the globe by 2031-end.
Challenges Regarding Varying Characteristics of Dry Powder Inhalers to Pave Opportunities for Medical Device Manufacturers
Regulatory pressures and changes in drug delivery market have driven innovation of the dry powder inhaler forward.
According to the World Health Organization (WHO), nearly 300 Mn people worldwide are affected by asthma, and approximately 240 Mn from the chronic obstructive pulmonary disease (COPD).
Over half of these patients combined prefer use of dry powder inhalers for treatment of their disease.
These devices have depicted great potential in effective and reliable drug delivery, with novel designs ensuring the possibility to overcome future compliance, cost, and safety challenges.
Some of the essential performance characteristics regarding dry powder inhalers are associated with dose-delivery, performances at varying airflows, and fine particle fraction content.
These characteristics may vary with respect to powder formulations, creating the need for fine tuning of the device or powder formulation or both combined for achieving optimal performance.
The requirement is particularly high in micro-dosing dry powder inhalers, which in turn is paving opportunities for medical device manufacturers in terms of innovations and advancements.
Growing adoption of unhealthy lifestyle, increasing geriatric population, and growing air pollution levels fuelling prevalence of various respiratory disorders are key factors driving expansion of the global dry powder inhaler market.
In addition, favorable government initiatives being taken across the globe for improving the healthcare infrastructure will further influence the market growth in the near future.
However, the fact that dry powder inhalers are not moisture-resistant remains a major challenge for manufacturers, as the medicine loses its properties when it comes in contact with the moisture.
Availability of effective alternatives such as nebulizers and electric pumps are expected to restrain adoption of dry powder inhalers.
Lack of awareness regarding these devices in low-income & underdeveloped countries may further hinder the market growth to a certain extent.
Request Sample Copy of Report @
https://www.futuremarketinsights.com/reports/sample/rep-gb-5150
Key Research Findings from FMI’s Report on Dry Powder Inhaler Market
- North America will continue to be the most lucrative region for growth of the dry powder inhaler market. Dry powder inhaler sales in the region will register the fastest expansion through 2031. Asia-Pacific excluding Japan (APEJ) is expected to be the second largest market for dry powder inhaler.
- Hospital pharmacies will continue to be the leading distribution channel for dry powder inhalers, with sales pegged to surpass 150,000 Mn units by 2031-end.
- Dry powder inhalers will continue to observe the largest application in the treatment of asthma, followed by chronic obstructive pulmonary disease. In addition, sales of dry powder inhalers for application in the treatment of asthma and pulmonary arterial hypertension are slated to exhibit a parallel growth through 2031.
Leading companies in the global dry powder inhaler market are focusing on the development of new generation products.
These market players are making huge investments in R&D activities associated with novel device architectures, particle engineering, and powder formulations.
Development of improved particle properties, along with efficient inhaler designs is expected to remain key strategies among the market players. Key market participants profiled in the report include Vectura Group Plc, MannKind Corporation, Chiesi Farmaceutici S.p.A., Boehringer Ingelheim GmbH, Teva Pharmaceutical Industries Limited, Cipla Ltd., Novartis AG, GlaxoSmithKline Plc, 3M Company, and Astrazeneca Plc.
Request a Complete TOC of this Report with figures @ https://www.futuremarketinsights.com/toc/rep-gb-5150
Key Market Segments Covered In Dry Powder Inhalers Industry Research
By Product :
- Single Dose Dry Powder Inhalers
- Multi Dose Dry Powder Inhalers
By Indication :
- Asthma
- Chronic Obstructive Pulmonary Disease (COPD)
- Pulmonary Arterial Hypertension
- Diabetes
- Cystic Fibrosis
By Function :
- Manually Operated Inhaler Devices
- Digitally Operated Inhaler Devices
By End User :
- Institutional Sales
- Hospital Pharmacies
- Cancer Research
- Office based Speciality Clinics
- Retail Sales
- Retail Pharmacies
- Drug Stores
- Mail Order Pharmacies
By Region :
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East and Africa (MEA)
Contact Sales for Further Assistance in Purchasing this Report @
https://www.futuremarketinsights.com/checkout/5150
Related Reports –
About Future Market Insights (FMI)
Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market.
It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years
Contact Us:
Future Market Insights
Unit No: 1602-006, Jumeirah Bay 2, Plot No: JLT-PH2-X2A
Jumeirah Lakes Towers, Dubai
United Arab Emirates
Editor Details
-
Company:
- MARKITWIRED
- Website:
